Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05619640
Other study ID # 21/360
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 1, 2021
Est. completion date September 30, 2022

Study information

Verified date November 2022
Source Haseki Training and Research Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

COVID-19 causes a wide spectrum of clinical illness, from upper respiratory symptoms to severe respiratory failure and death. Several plasma biomarkers -such as IL-6, C-reactive protein (CRP), D-dimer, the neutrophil-to-lymphocyte ratio, and ferritin, among others- have been studied as markers of disease severity and prognosis. Besides, as alveolar damage biomarkers such as Surfactant protein D (SP-D), Krebs von den Lungen-6 (KL-6), and soluble Receptor for Advanced Glycation end products (sRAGE) can be used in lung diseases as well as COVID-19 pneumonia. The investigators hypothesized that serum SP-D, KL-6 and sRAGE levels increases in the setting of COVID-19 pneumonia. In this prospective study the investigators aimed to determine the clinical value of serum KL-6, SP-D and sRAGE levels as a prognostic marker in children with COVID-19 patients. In the literature review, it has been determined that there is no study conducted or published in pediatric patients for this purpose, and it is aimed that our study will be a pioneer study on this subject.


Description:

It aimed to determine the clinical value of serum KL-6, SP-D and sRAGE levels as a prognostic marker in children with COVID-19 patients.. This study was planned as a case-control study with patients hospitalized in the Haseki Training and Research Hospital Pediatric Infection Ward. A total of 150 children, including at least 30 patients in each group were included in the study. The study group was divided into three groups according to COVID-19 WHO clinical progression Scale: uninfected (Group 1), mild (Group 2) and moderate (group 3). In order to investigate the relationship between disease severity and alveolar damage, serum KL-6, SP-D and sRAGE levels and high sensitive C-reactive protein were measured. These biomarkers levels were compared between three groups.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date September 30, 2022
Est. primary completion date June 21, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Month to 18 Years
Eligibility Inclusion Criteria: 1. Between 1 month-18 years old 2. SARS-CoV-2 PCR positive 3. Not having a chronic disease (cystic fibrosis, etc.) 4. Volunteering to participate in the study 5. Healty Control Exclusion Criteria: 1. Having a chronic disease 2. Patients who could not be diagnosed with SARS-CoV-2 infection by laboratory and/or radiological examinations 3. Not volunteering to participate in the stud

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Turkey Haseki Training and Research Hospital Istanbul

Sponsors (2)

Lead Sponsor Collaborator
Haseki Training and Research Hospital Saglik Bilimleri Universitesi

Country where clinical trial is conducted

Turkey, 

References & Publications (4)

Determann RM, Royakkers AA, Haitsma JJ, Zhang H, Slutsky AS, Ranieri VM, Schultz MJ. Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients. BMC Pulm Med. 2010 Feb 16;10:6. doi: 10.1 — View Citation

Kommoss FKF, Schwab C, Tavernar L, Schreck J, Wagner WL, Merle U, Jonigk D, Schirmacher P, Longerich T. The Pathology of Severe COVID-19-Related Lung Damage. Dtsch Arztebl Int. 2020 Jul 20;117(29-30):500-506. doi: 10.3238/arztebl.2020.0500. — View Citation

Sivapalan P, Bonnesen B, Jensen JU. Novel Perspectives Regarding the Pathology, Inflammation, and Biomarkers of Acute Respiratory Distress Syndrome. Int J Mol Sci. 2020 Dec 28;22(1). pii: E205. doi: 10.3390/ijms22010205. Review. — View Citation

WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020 Aug;20(8):e192-e197. doi: 10.1016/S1473-3099(20)30483-7. Epub 2020 Jun 12. Review. Erratum in: Lancet Infect Dis. 2020 Oct;20(10):e250. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Relationship between SARS-CoV-2 severity and alveolar damage biomarker levels Serum samples were obtained from all patients on admission. The data set divided into three groups according to COVID-19 WHO Clinical progression scale. The Surfactant protein D, Krebs von den Lungen-6, high sensitive C-reactive protein and soluble receptor for Advanced Glycation end products levels were determined by using ELISA kits. These biomarker levels were compared between three groups by using Kruskal-Wallis test and Tukey post test for multiple comparisons. baseline
See also
  Status Clinical Trial Phase
Completed NCT03563196 - Diagnosis Of Pulmonary Complications After Cardiac Surgery In Children
Completed NCT02553486 - Internationally Adopted Children Quality of Life N/A
Completed NCT02903134 - Early Risk of Asthma in Children Exposed to In-utero Maternal Obesity
Completed NCT02918890 - Intensive Unimanual (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegia N/A
Active, not recruiting NCT01874847 - PLAY GAME: Post-concussion Syndrome in Youth - Assessing the GABAergic Effects of Melatonin Phase 2/Phase 3
Enrolling by invitation NCT01971827 - Effectiveness of a Physical Activity Intervention to Prevent Obesity and Improve Academic Performance N/A
Enrolling by invitation NCT01971840 - Effectiveness of a Physical Activity Intervention on Preventing Obesity During the Adiposity Rebound Period. N/A
Completed NCT01738308 - The Effects of Healing Touch on Post Operative Pediatric Patients N/A
Completed NCT01943760 - Tamadol Wound Infiltration in Children Under Inguinal Hernioplasty Phase 4
Completed NCT01864811 - Effect of Baby-CIMT in Infants Younger Than 12 Months N/A
Completed NCT01693926 - Effect of Physical Activity an Stress in Children N/A
Completed NCT01323010 - Efficacy and Safety of Increasing Doses of Inhaled Albuterol in Children With Acute Wheezing Episodes N/A
Completed NCT01277224 - Effectiveness of a Physical Activity Intervention on the Obesity of Schoolchildren N/A
Active, not recruiting NCT00989547 - Cord Blood Infusion for Type 1 Diabetes Mellitus (T1DM) Phase 1
Completed NCT04051723 - Pre-emptive Scalp Infiltration With Dexamethasone Plus Ropivacaine for Post-Craniotomy Pain in Children Phase 4
Completed NCT03236337 - Effectiveness of MOVI Interventions on Adiposity, Cognition and Subclinical Atherosclerosis: MOVI-daFit! N/A
Completed NCT03236363 - Effectiveness of MOVI Interventions on Adiposity, Cognition and Motor Competence: MOVI-da10! N/A
Not yet recruiting NCT03427697 - Effect of VR and Accommdation Relax on Controlling Myopia in Children N/A
Completed NCT05603507 - Inspiratory Muscle Training in Children With Chest Burn N/A
Not yet recruiting NCT06267339 - Effects of Transcranial Random Noise Stimulation on Motor Learning in Typically Developing Adolescents Early Phase 1